NIH VideoCast - Antiviral and Anti-Inflammatory Approaches to COVID-19

Skip Navigation

Antiviral and Anti-Inflammatory Approaches to COVID-19

Loading... Loading video...

1,147 Views

Air date:	Thursday, January 7, 2021, 12:00:00 PM Time displayed is Eastern Time, Washington DC Local
Views:	Total views: 1,147 (829 Live, 318 On-demand)
Category:	COVID-19
Runtime:	01:01:57
Closed captioning:	Check box to display CC outside of the video Note: You can drag the captioning window around and resize it
Description:	COVID-19 Scientific Interest Group Dr. Beigel is associate director for clinical research in the NIAID Division of Microbiology and Infectious Diseases. In this position, he helped the implementation and execution of the Adaptive COVID-19 Treatment Trial (ACTT) platform. ACTT-1 led to the licensure of remdesivir; ACTT-2 supported the Emergency Use Authorization of baricitinib in COVID-19. Remdesivir improves outcomes for hospitalized adult patients with COVID-19. Despite its use, there continues to be significant morbidity and mortality. Disease severity might be due to a dysregulated inflammatory response. Modifying the inflammatory state may improve clinical outcomes. This talk will review current antiviral and anti-inflammatory therapeutics for the treatment of COVID-19, with a focus on the ACTT-1 and ACTT-2 trials. For more information go to https://oir.nih.gov/sigs/covid-19-scientific-interest-group

NLM Title:	Antiviral and anti-Inflammatory approaches to COVID-19 / John Beigel.
Author:	Beigel, John. National Institutes of Health (U.S.). COVID-19 Scientific Interest Group,
Publisher:
Abstract:	(CIT): Dr. Beigel is associate director for clinical research in the NIAID Division of Microbiology and Infectious Diseases. In this position, he helped the implementation and execution of the Adaptive COVID-19 Treatment Trial (ACTT) platform. ACTT-1 led to the licensure of remdesivir; ACTT-2 supported the Emergency Use Authorization of baricitinib in COVID-19. Remdesivir improves outcomes for hospitalized adult patients with COVID-19. Despite its use, there continues to be significant morbidity and mortality. Disease severity might be due to a dysregulated inflammatory response. Modifying the inflammatory state may improve clinical outcomes. This talk will review current antiviral and anti-inflammatory therapeutics for the treatment of COVID-19, with a focus on the ACTT-1 and ACTT-2 trials.
Subjects:	Anti-Inflammatory Agents--therapeutic use Antiviral Agents--therapeutic use COVID-19--drug therapy Clinical Trials, Phase I as Topic Clinical Trials, Phase II as Topic
Publication Types:	Lecture Webcast

NLM Classification:	WC 506.2
NLM ID:	101775925
CIT Live ID:	41233
Permanent link:	https://videocast.nih.gov/watch=41233

Related Videos...